Phoresy, the phenomenon at the heart of this research, is a form of temporary symbiosis in which a smaller organism attaches itself to a larger one purely for transport. It is especially common among mites, minute and weakly mobile arthropods that exploit ephemeral, patchily distributed resources such as carrion. While phoresy has traditionally been viewed as a benign commensal arrangement, scientists increasingly recognize that such relationships can slide along a continuum from commensalism to mutualism or even parasitism, depending on the costs and benefits experienced by both partners. In highly specific phoresy, where the association is long-term or permanent, the evolutionary consequences can be profound, including synchronization of life cycles, cospeciation, or a transition toward parasitic dependence.

The mites in question belong to the Uroobovella nova species complex, a group of cryptic species within the order Uropodina that are transported exclusively by burying beetles of the genus Nicrophorus. Unlike most uropodine mites, which hitch rides on a broad spectrum of insect carriers, U. nova deutonymphs, the specialized juvenile dispersal stage, depend entirely on burying beetles. Previous molecular work demonstrated that what was once considered a single generalist species actually comprises at least five cryptic species associated with different beetle hosts. Yet compared with the better-studied Poecilochirus mite–burying beetle system, in which mites ride beetles into underground brood chambers and reproduce alongside them, the Uroobovella interaction remains poorly understood.

Led by Daria Bajerlein of Adam Mickiewicz University in Poznań, the research team set out to determine whether different burying beetle species play equal roles in the local dispersal of these mites. Their previous work on the common European burying beetle Nicrophorus vespilloides had documented an extraordinarily high mite prevalence of roughly 90 percent, with an average of nearly 25 deutonymphs per beetle, strong site selectivity on the host body, and a slight preference for females. The new study focused on three additional, less abundant species collected from the same woodland: N. vespillo, N. humator, and N. interruptus. The central question was whether these species serve as primary carriers or merely incidental hosts.

The fieldwork took place in the Niepołomice Forest, a roughly 110-square-kilometer woodland near Kraków in southern Poland. Beetles were collected as bycatch in flight interception traps originally deployed for saproxylic beetles in 2018 and 2019. The traps used ethylene glycol as a preservative, which had the crucial side effect of immobilizing attached mites and preventing them from moving between hosts, thereby preserving the original infestation patterns. From the material gathered between mid-July and mid-September 2018, the researchers analyzed 880 beetles: 275 N. humator, 315 N. interruptus, and 290 N. vespillo. Every specimen was dissected to determine sex, measured for body size via pronotum width, and examined under magnification for both attached mites and empty pedicels, the stalk-like attachment structures that remain as evidence of a mite’s prior presence.

The statistical analysis employed generalized linear models to test the effects of beetle species, sex, and body size on both the prevalence of infestation, meaning the proportion of beetles carrying mites, and the intensity of infestation, meaning the average number of mites per infested beetle. A generalized linear mixed model was used to examine mite distribution across eleven body regions on the left and right sides of each beetle. The results were unambiguous in several respects. Nicrophorus vespillo proved to be the most frequently infested species, followed by N. humator, with N. interruptus the least infested of all. N. vespillo and N. humator also carried the greatest numbers of mites, while N. interruptus hosted significantly fewer. Notably, N. interruptus had never before been reported as a carrier of U. nova mites.

The sexual bias was equally striking. Across the sample, male beetles exhibited both higher mite prevalence and higher infestation intensity than females, and this pattern was particularly pronounced in N. vespillo and N. humator. Males of these two species carried the heaviest mite loads, whereas in N. interruptus no sex-related difference in mite number was detected. The researchers suggest that these sex-specific infestation patterns likely stem from differences in breeding biology between males and females. Biparental cooperation, in which both sexes prepare brood chambers and provide parental care together, has been well documented in N. vespilloides and N. vespillo but not in the other species examined. Because deutonymphs disperse by riding beetles to and from breeding sites, variation in how each sex uses carcasses and brood chambers could strongly influence which individuals end up carrying the mites.

Perhaps the most conceptually important finding concerns body size. The three beetle species differed significantly in size, with N. humator the largest and N. interruptus the smallest, yet variation in body size was not a significant predictor of mite prevalence, intensity, or distribution. This directly challenges the widespread ecological assumption that larger hosts inevitably carry more symbionts. The point is reinforced by a comparison with the team’s earlier work: N. vespilloides, the smallest of all four species studied across the two projects, with a mean pronotum width of just under five millimeters, was more heavily infested than the much larger N. humator. The finding aligns with a growing body of parasitological literature suggesting that host size does not consistently determine host suitability for symbionts, and that behavioral and ecological factors often outweigh simple morphological scaling.

The spatial distribution of mites on their carriers added another layer of complexity. In all three species, more deutonymphs attached to anterior body regions than to posterior ones, with the prothorax presternum, the plate on the underside of the front section of the thorax, serving as the preferred attachment site, along with the lateral margins of the ventral pronotum and the coxae of the forelegs. However, the fine-grained patterns were species- and sex-specific. In N. humator, mites were distributed relatively evenly across favored regions, while in N. vespillo the dominance of the presternum was more pronounced. In N. interruptus, deutonymphs showed an unusual additional preference for the femur of the left hindleg, the only case in which mite numbers differed between the left and right sides of the body. Males, overall, bore more heavily infested body regions than females, with the most pronounced intersexual differences appearing at the presternum, and females of N. humator and N. vespillo showed more even mite distribution across the body than males.

Why would these patterns exist? The researchers propose that the mites examined likely represent a single cryptic species, Uroobovella sp. 3, previously identified through molecular markers on N. vespilloides and N. vespillo, possibly with host races associated with N. humator and N. interruptus. Differences in infestation among beetle species probably arise not from different mite species but from interspecific differences in carrier biology, particularly breeding behavior, seasonal activity, population dynamics, body surface morphology, and grooming habits. Niche overlap between beetle species also matters: N. vespilloides and N. vespillo show consistently high overlap in their seasonal activity, which may facilitate host switching by the mites, whereas overlap with the forest-dwelling N. humator is low in spring and only increases later in the year. Importantly, direct switching on carcasses appears unlikely, because uropodine deutonymphs detach only in suitable microhabitats and are anchored by pedicels that limit movement between hosts. Host switching most plausibly occurs when a breeding chamber is taken over by another beetle species, allowing the next mite generation to disperse with the new host’s offspring.

The study’s conclusions carry weight beyond the carrion beetle community. At the local scale, individual burying beetle species evidently play different roles in mite dispersal, with N. vespilloides confirmed as the primary carrier, followed by N. vespillo and N. humator, and N. interruptus playing a far smaller role. The demonstration that sex can consistently shape symbiont loads, while size does not, adds nuance to how ecologists model host–symbiont associations. The authors call for future work on local genetic differentiation within the U. nova complex to clarify its taxonomy, and for laboratory experiments observing the mites inside beetle brood chambers, their impacts on hosts, and their interactions with competing Poecilochirus mites. Such research promises to illuminate how phoretic symbiosis is shaped when mites and beetles coevolve within the transient, fiercely contested world of vertebrate carrion, where every carcass is both a nursery and a highway junction for some of nature’s smallest travelers.

Klebsiella pneumoniae is a Gram-negative bacterium that colonizes the human gut and mucosal surfaces, but it can cause severe, life-threatening infections including pneumonia, bloodstream infections, meningitis, and liver abscesses. The bacterium has long been a fixture of hospital-acquired infection surveillance because of its remarkable capacity to acquire and disseminate antibiotic resistance genes via mobile genetic elements, particularly plasmids. Carbapenems, a class of last-resort beta-lactam antibiotics reserved for the most serious multidrug-resistant infections, have historically been the therapeutic mainstay for treating serious K. pneumoniae infections. The emergence of strains resistant to these agents has therefore been recognized by the World Health Organization as a critical public health threat requiring urgent global attention.

The research team, led by Montaser M. Y. Amro, Aysegul Bostanci, and Buket Baddal of Near East University’s Faculty of Medicine and DESAM Research Institute, set out to determine the prevalence of beta-lactamase genes and hypervirulence-associated markers among clinical carbapenem-resistant K. pneumoniae isolates circulating in Cyprus. Their methodology combined classical microbiological phenotyping with targeted molecular detection of resistance and virulence determinants, providing a comprehensive snapshot of what is circulating in a single tertiary care facility.

The isolates were first identified to the species level and subjected to antimicrobial susceptibility testing using the VITEK-2 automated system, a widely adopted platform in clinical microbiology laboratories. Carbapenem resistance was confirmed using the Modified Hodge test, a phenotypic assay in which a carbapenem-susceptible indicator strain is used to detect carbapenemase production by the test isolate. The results were striking: 75 of the 96 isolates, or 78.1 percent, were confirmed as carbapenem-resistant K. pneumoniae by the Modified Hodge test. This figure alone underscores the substantial burden of carbapenem resistance within the hospital’s patient population.

Molecular characterization of the carbapenemase genes revealed a clear predominance of blaOXA-48, which was detected in 84.0 percent of the carbapenem-resistant isolates. The OXA-48-type carbapenemases, originally described in Turkey and now widespread across Europe, the Middle East, and North Africa, hydrolyze carbapenems and penicillins but spare extended-spectrum cephalosporins. Their dominance in this Cypriot cohort is consistent with regional epidemiological patterns documented by the European Centre for Disease Prevention and Control, which has repeatedly highlighted OXA-48 as the most prevalent carbapenemase in Enterobacterales across the EU and EEA.

The remaining carbapenemase determinants were less frequent but clinically significant. The metallo-beta-lactamase gene blaIMP was found in 8.0 percent of isolates, blaVIM in 4.0 percent, and blaNDM in 2.7 percent. New Delhi metallo-beta-lactamases are particularly feared because they hydrolyze nearly all beta-lactam antibiotics, including carbapenems, and are often embedded in plasmids that carry additional resistance determinants. Perhaps most concerning was the detection of co-existing carbapenemase genes in eight isolates. These strains harbored combinations of blaOXA-48 with either blaNDM, blaIMP, or blaVIM, meaning they carry both a serine carbapenemase and a metallo-beta-lactamase on the same genetic background. Such co-carriage severely constrains therapeutic options and increases the risk that treatment with any single beta-lactam-beta-lactamase inhibitor combination will fail, as the two enzyme classes have complementary hydrolysis spectra that can compensate for each other’s weaknesses.

The hypervirulence component of the investigation is what elevates this study from a routine resistance survey to a report of genuine epidemiological significance. Hypervirulent K. pneumoniae is a distinct pathotype characterized by enhanced ability to cause invasive, metastatic infections in otherwise healthy individuals. Classical hypervirulent strains were first recognized in East Asia, where they caused dramatic cases of community-acquired liver abscess with metastatic spread to the eyes, central nervous system, and other sites. These strains typically overproduce capsular polysaccharide, giving colonies a hypermucoviscous appearance, and produce additional iron-scavenging systems that enhance survival within the host.

To assess hypervirulence potential, the researchers performed the string test, a simple phenotypic assay in which a bacterial colony is touched with an inoculation loop and the resulting string is measured; a positive result, defined as a string extending more than 5 millimeters, indicates hypermucoviscosity associated with hypervirulent potential. They also used conventional polymerase chain reaction to screen for three hypervirulence-associated genes: iucA, which encodes a key enzyme in aerobactin synthesis; peg-344, a metabolic transporter gene associated with hypervirulent strains; and iroB, involved in salmochelin siderophore synthesis.

Of the 75 carbapenem-resistant isolates, 32, or 42.7 percent, exhibited the hypermucoviscous phenotype on string testing. This is a remarkably high proportion for a carbapenem-resistant population and suggests that hypervirulence traits are well established within the resistant strains circulating at the hospital. At the genetic level, the aerobactin synthesis gene iucA was detected in 44 isolates, representing 58.7 percent of the carbapenem-resistant cohort. Aerobactin is a siderophore, an iron-chelating molecule that allows the bacterium to scavenge iron from its host, and it is widely regarded as one of the most reliable molecular markers of hypervirulent K. pneumoniae. Previous studies have shown that aerobactin-positive strains exhibit significantly enhanced virulence in experimental infection models compared to aerobactin-negative strains.

Interestingly, the peg-344 and iroB genes were not detected in any of the examined isolates. This finding suggests that the Cypriot strains possess a partially assembled hypervirulence genetic repertoire rather than the complete complement typically found in classical hypervirulent K. pneumoniae clones. It also highlights an ongoing debate within the field regarding the prudent use of the term “hypervirulence” when applied to carbapenem-resistant isolates, as some researchers have cautioned that partial virulence gene carriage may not equate to the clinical severity associated with classical hypervirulent strains. Nevertheless, the combination of carbapenem resistance with aerobactin production and a hypermucoviscous phenotype in nearly half of the resistant isolates represents a convergence of traits that has historically been associated with worse patient outcomes, including higher mortality rates in bloodstream and intra-abdominal infections.

The convergence of hypervirulence and carbapenem resistance in a single strain is a relatively recent phenomenon in the evolution of K. pneumoniae. For many years, these two traits appeared to occupy separate evolutionary niches: classical multidrug-resistant hospital strains tended to be less virulent, while hypervirulent community strains remained susceptible to most antibiotics. However, reports from China and increasingly from Europe have documented the emergence of strains that carry both resistance determinants and virulence plasmids, often through horizontal transfer of virulence plasmids into resistant backgrounds or acquisition of resistance plasmids into virulent clones. The Cypriot findings add the eastern Mediterranean island to the growing list of regions where this convergence has been documented.

The clinical implications are substantial. Carbapenem-resistant K. pneumoniae infections already carry high mortality because of limited treatment options, typically restricted to combinations of tigecycline, colistin, ceftazidime-avibactam, and meropenem in various permutations. Adding hypervirulence traits to this picture could make infections even more difficult to manage, particularly in vulnerable patient populations such as the elderly, immunocompromised individuals, and those with indwelling medical devices. The presence of metallo-beta-lactamases in some isolates further complicates the therapeutic landscape, as these enzymes are not inhibited by newer beta-lactamase inhibitors such as avibactam.

The Cyprus study also carries regional significance given the island’s position as a crossroads between Europe, the Middle East, and North Africa, and given its proximity to countries with high endemic rates of carbapenem resistance. Cross-border movement of resistant organisms through medical tourism, patient transfer, and population mobility is well documented, and Cyprus’s role as both a destination and a transit point makes it a potentially important location for monitoring the spread of these convergent strains.

The authors of the study emphasize that this is the first report describing carbapenem-resistant K. pneumoniae isolates with hypervirulence-associated characteristics in Cyprus and stress the need for continuous molecular surveillance and stringent infection control measures to prevent further dissemination within the healthcare environment. Their findings serve as a stark reminder that the evolution of dangerous bacterial pathogens does not respect national boundaries and that vigilant, genomics-informed surveillance remains one of the most effective tools available for early detection and containment of emerging threats. As antimicrobial resistance continues to climb globally, studies such as this one provide critical baseline data that will inform future monitoring, infection prevention strategies, and therapeutic decision-making in the region and beyond.

Expression quantitative trait loci are genomic positions, typically single nucleotide variants, that correlate with differences in the activity of nearby genes. In classical eQTL studies, which aggregate gene expression measurements across whole tissues, these associations reveal only the average effect of a variant across a mixture of cell types. That averaging is a serious limitation for immunology, because peripheral blood contains dozens of specialized cell populations—T cells, natural killer cells, monocytes, B cells, and many rarer intermediates—each with its own regulatory grammar. A variant that strongly boosts a gene in natural killer cells may be invisible in a bulk measurement dominated by monocytes. By pairing each donor’s genome with single-cell transcriptomes, the researchers could test the association between genotype and expression separately within each cell population, resolving effects that bulk approaches blur away.

The technical pipeline behind the study was substantial. Whole-genome sequencing data were processed through established variant-calling workflows, with germline small variants identified using the Strelka2 caller, following best practices endorsed by the Global Alliance for Genomics and Health for benchmarking variant calls. Coverage calculations were performed with Mosdepth, and sequencing quality was assessed against community standards to ensure that the genetic data underpinning the eQTL analysis were reliable. On the transcriptomic side, single-cell RNA-seq data from the 230,000 PBMCs were integrated across donors using the Harmony method, a widely adopted algorithm that corrects for batch effects and donor-specific technical noise while preserving genuine biological differences between cell types. Cells were then classified into 18 populations spanning the major branches of the immune system, providing the cellular resolution required for cell-type-specific association testing.

With genotypes and cell-type-resolved expression in hand, the team carried out cis-eQTL mapping using Matrix eQTL, a computational framework designed to perform the enormous matrix operations required for fast association testing across millions of variants and thousands of genes. The result was a catalog of 1,233,644 cis-eQTLs distributed across the 18 cell types. Importantly, this was not simply a numbers exercise. The researchers subjected their findings to a series of validation and interpretive analyses designed to ask whether the variants they detected showed the hallmarks of genuine regulatory elements, and, more provocatively, what evolutionary forces have shaped them.

One of the most intriguing findings to emerge from these secondary analyses concerns evolutionary conservation. When the team examined the genomic regions harboring their strongest eQTLs, they found that the most statistically significant associations tended to sit in less conserved regions of the genome—stretches of DNA that have diverged relatively rapidly between species. These variants were also concentrated in the regulatory regions of more divergent genes. This pattern suggests that immune gene regulation is an evolutionary hotspot, consistent with the well-documented observation that genes involved in host defense are frequent targets of positive selection. Rapid turnover of regulatory elements may allow populations to adapt to changing pathogen landscapes, but it may also help explain why immune-related variants are a rich source of susceptibility to chronic inflammatory and autoimmune disease in modern humans. The finding carries a double edge: the same regulatory flexibility that enabled adaptation to ancient pathogens may predispose contemporary genomes to misfire.

To move from statistical association to mechanistic understanding, the researchers turned to deep learning models of cis-regulatory sequence. Neural networks trained on genomic data can learn the relationship between DNA sequence and regulatory function, predicting how transcription factors bind to specific sequence contexts and how single-base changes alter those interactions. Drawing on approaches pioneered by tools such as DeepSEA, Basset, and the Enformer-style sequence models developed in recent years, the team applied these computational models to their eQTL catalog to ask, for each variant, which transcription factor binding sites are disrupted and in which cellular context that disruption matters. This step transformed the analysis from a list of correlated positions into a functional hypothesis-generating resource: each eQTL could now be annotated with a predicted mechanism of action grounded in sequence-level regulatory biology.

The functional analysis focused on genes with well-established roles in immunity, including NKG7, members of the HLA family, MIF, and MS4A1. NKG7 encodes a protein essential for the cytotoxic function of natural killer cells and CD8 T cells, involved in the trafficking of lytic granules that deliver the killing blow to infected or malignant target cells; variants affecting its expression could plausibly modulate antiviral and antitumor immunity. HLA genes, which encode the human leukocyte antigen molecules that present viral peptides to T cells, are among the most polymorphic loci in the human genome and have been repeatedly implicated in COVID-19 susceptibility and severity. MIF, the macrophage migration inhibitory factor, is a potent inflammatory mediator whose circulating levels correlate with severe COVID-19 pneumonia. MS4A1, better known as CD20, defines B cells and is the target of widely used monoclonal antibody therapies. By tracing how variants influence the expression of these genes through disrupted transcription factor binding—including factors such as those involved in myeloid and lymphoid differentiation—the study connected genetic variation to plausible cellular mechanisms.

The disease context of the study is explicit in its framing. Prior work by overlapping teams had used single-cell transcriptomics to identify immune cell signatures associated with severe Delta-variant COVID-19, and large consortia had shown that severe disease is marked by a dysregulated myeloid cell compartment. The GWAS Catalog lists numerous loci associated with COVID-19 outcomes, but translating those associations into functional biology has remained a central challenge for the field. The new eQTL resource provides a bridge: because it assigns regulatory variants to specific immune cell types and annotates their predicted effects on gene expression, it can be used to prioritize candidate causal variants among the many statistical associations emerging from disease-genetic studies. The authors also point toward broader applications, noting parallels with single-cell eQTL studies in brain, autoimmune disease, and other contexts that have revealed how cell-type-specific regulation shapes genetic risk.

The scale of the cellular census deserves emphasis. Thirty donors may sound modest compared with the million-person cohorts of cardiovascular genetics, but single-cell eQTL studies trade sample size for resolution: every donor contributes tens of thousands of individual cells, each measured across the whole transcriptome. The 230,000-cell dataset allowed the researchers to detect eQTLs not only in abundant populations like CD4 T cells and monocytes but in rarer states such as intermediate monocytes and specific lymphocyte subsets, where regulatory effects would be hopelessly diluted in bulk analysis. The identification of 18 cell-type-resolved regulatory landscapes from this relatively small cohort illustrates the power of the approach, and the authors’ analytical strategy—conservation analysis, transcription factor modeling, and pathway interrogation—provides a template that larger consortia are likely to follow as single-cell eQTL mapping matures.

Methodologically, the study also underscores how much of modern genomics depends on careful assembly of open computational tools. Beyond the core machinery of variant calling and eQTL mapping, the researchers drew on annotation frameworks for regulatory elements derived from more than a thousand epigenomic datasets, packages for gene ontology and pathway enrichment, tools for predicting DNA shape features that influence transcription factor binding, and simulation frameworks for testing the significance of overlaps between genomic intervals. This layered infrastructure allowed a single research group to integrate population genetics, transcriptomics, chromatin biology, and machine learning into a coherent narrative about how sequence variation becomes functional variation in the immune system.

The limitations of the study are those inherent to its design. A cohort of 30 individuals restricts statistical power for detecting rarer variants and weaker regulatory effects, and the donor population limits generalizability across ancestries—an important consideration given that eQTL effects and linkage patterns differ among populations. The deep learning predictions, while mechanistically informative, remain computational hypotheses that would need experimental validation through reporter assays or CRISPR-based perturbation of individual variants. Nevertheless, the study’s value lies in the framework it establishes: a complete chain from genome sequence, through cell-type-resolved expression, to predicted transcription factor mechanism, anchored to a disease of global significance.

As single-cell sequencing costs continue to fall and paired genotyping-transcriptomics cohorts grow, resources of this kind are expected to expand rapidly in scale and diversity. What this study demonstrates is that the payoff of such investment is not merely a longer list of associations, but a progressively sharper picture of the regulatory code that governs human immunity—and with it, new opportunities to understand, predict, and ultimately intervene in diseases where the immune system holds the balance between recovery and catastrophe. For COVID-19, whose genetic architecture continues to be dissected years after the pandemic’s peak, that sharper picture may help explain at last why the same virus produces a mild illness in one person and a life-threatening one in another.

Cefiderocol occupies a unique position in modern infectious disease medicine. Approved as a treatment for multidrug-resistant Gram-negative infections, it is a so-called siderophore-conjugated cephalosporin, a molecule engineered to exploit the bacterium’s own starvation reflex. Under iron-poor conditions—which prevail inside the human body—bacteria desperate for the metal import iron-chelating compounds called siderophores. Cefiderocol masquerades as one of these scavengers, binding iron on its catechol moiety and hitchhiking through the bacterium’s dedicated iron transport channels, the Cir, Fiu and Piu transporters, past the outer membrane barrier that defeats ordinary antibiotics. Once inside, the drug behaves as a classical beta-lactam: it binds and inactivates penicillin-binding proteins, the enzymes that assemble and cross-link the bacterial cell wall, halting construction of the organism’s protective exoskeleton. This Trojan-horse strategy gave clinicians hope that cefiderocol could succeed where carbapenems and cephalosporins had failed, particularly against carbapenem-resistant Enterobacteriaceae, which the World Health Organization ranks among the most critical pathogens for new antibiotic development.

Yet the drug’s Achilles heel was apparent from early clinical and surveillance studies. Because cefiderocol depends on iron transport systems to reach its target, bacteria can defend themselves simply by shutting down or mutating those entry doors. Many documented resistance cases involve mutations in the TonB-dependent transport machinery, loss of the PiuD channel, alterations in iron regulation through the Fur protein and the small RNAs RyhB and PrrF, or the amplification of beta-lactamase enzymes, including structural variants of enzymes such as CMY that hydrolyze the drug more efficiently. Plasmid-borne determinants can spread these defenses horizontally between strains, amplifying the threat. The Spanish team, however, found something strikingly different when they sequenced Klebsiella pneumoniae isolates collected from their patient before and after cefiderocol therapy.

Using whole-genome sequencing and comparative genomics, the researchers compared the pair of isolates at single-nucleotide resolution. The plasmid architecture of the bacterium—the constellation of extrachromosomal DNA elements that often carry resistance genes—remained conserved between the susceptible and resistant versions. There was no acquisition of a new beta-lactamase, no introduction of a foreign iron-uptake determinant, no dramatic genetic overhaul. Instead, the analysis revealed eighty-two chromosomal variants that had accumulated or been selected during therapy, and within this set two mutations emerged as the leading candidates for the resistance phenotype. The first, and most consequential, was a single missense substitution in the ftsI gene: a change from glycine to valine at position 306 of the FtsI protein, designated G306V. The second was E91K in AcrR, a regulator of the AcrAB-TolC multidrug efflux pump, hinting at a possible secondary contribution through enhanced drug export.

The significance of the FtsI mutation lies in the biology of the protein itself. FtsI, better known in the field as penicillin-binding protein 3, or PBP3, is an essential transpeptidase that catalyzes the cross-linking of peptidoglycan during cell division, building the septum that separates one daughter cell from another. Like all beta-lactam targets, it carries a catalytic serine residue—in this case S307—around which the antibiotic must nestle to form the covalent bond that permanently disables the enzyme. The glycine at position 306 sits immediately adjacent to this catalytic linchpin. Using structural modeling, the researchers showed that swapping the smallest amino acid, glycine, for the bulkier branched-chain valine produces a dramatic volumetric increase in the local side-chain architecture. The new valine juts into the active-site cavity, creating steric hindrance that could physically impede cefiderocol from approaching and properly positioning itself relative to the catalytic serine. In essence, the bacterium did not destroy the drug, pump it out, or block its entry through iron transporters—it simply altered the lock so that the key no longer fits.

This mechanism distinguishes the Spanish case from the predominant narratives in the global molecular epidemiology of cefiderocol resistance, and that distinction carries both scientific and clinical weight. Target-site alteration of PBP3 has long been recognized as a resistance route in Pseudomonas aeruginosa, where penicillin-binding protein mutations are a leading cause of cefiderocol failure, but it has remained insufficiently defined in Klebsiella pneumoniae. By demonstrating that a single amino-acid substitution adjacent to the catalytic serine can plausibly confer resistance in this organism, the study fills an important gap and suggests that surveillance programs may be looking in the wrong place—or at least not in enough places—when they screen for the emergence of treatment failure.

The team did not stop at a single case. To assess how common the G306V substitution is across the global bacterial population, they performed large-scale genomic screening of publicly available Klebsiella pneumoniae genomes, including isolates known to be cefiderocol-resistant. The result was reassuring but nuanced: substitutions affecting ftsI, including at this specific position, are extremely rare, even among resistant isolates. The researchers caution, however, that clonal expansion of a successful resistant lineage cannot be ruled out, meaning a rare mutation today could become a clinical problem tomorrow if the right selective pressure persists. The rarity also strengthens the inference that the mutation arose under therapy in this individual patient rather than being imported from the community or hospital environment.

The companion mutation in AcrR adds an additional layer of mechanistic intrigue. AcrR is the transcriptional repressor of the acrAB operon, which encodes one of the principal multidrug efflux pumps of Enterobacteriaceae. Loss-of-function or altered-function mutations in AcrR can de-repress the pump, flooding the periplasm with export machinery capable of lowering intracellular concentrations of a wide range of compounds, including beta-lactams under some conditions. An E91K substitution could plausibly perturb the repressor’s function, and the authors position it as a key candidate contributor that may act in concert with the PBP3 alteration. Such combined mechanisms—reduced drug access at the target and enhanced drug removal from the cell—are a recurring theme in the evolution of high-level resistance, and their convergence in a single treatment episode illustrates the flexible, heterogeneous nature of how bacteria respond to this last-line agent.

For clinicians and public health officials, the implications extend beyond basic biology. Cefiderocol is frequently deployed against infections caused by carbapenemase-producing organisms when no other option remains, and therapeutic drug failure in such settings can be fatal. The study’s central recommendation is that ftsI—specifically the region within or proximal to the active site—be incorporated into genomic surveillance frameworks for cefiderocol resistance. As whole-genome sequencing becomes faster and cheaper, real-time detection of target-site mutations could inform antibiotic stewardship decisions, alert infection control teams to the emergence of resistant subpopulations during therapy, and guide the development of diagnostic assays that flag resistance before clinicians lose precious time. The findings also resonate with the broader epidemiological picture in which cefiderocol resistance is not the product of a single dominant mechanism but of many parallel evolutionary solutions, each requiring its own watchfulness.

The research emerged from a close collaboration between the Clinical Microbiology Laboratory and the Infectious Diseases Department at Miguel Servet University Hospital, together with the University of La Rioja and international partners including the University of Debrecen in Hungary. The study was approved by the ethics committee of Aragón and conducted in accordance with the Declaration of Helsinki, with open-access funding provided through the CRUE-CSIC agreement with Springer Nature. The corresponding author, Alexander Tristancho-Baró, and co-authors including Carmen Torres and Antonio Rezusta acknowledge the laboratory technicians and clinical teams whose sample processing made the before-and-after genomic comparison possible.

As the arms race between antibiotics and bacteria enters its second century, the Spanish study is a reminder that evolution rarely follows a script. Cefiderocol was designed to outsmart one of the most formidable defense architectures in biology, and in many patients it does exactly that. But in at least one infection, a quiet change of a single molecular letter—glycine to valine, at the doorstep of the enzyme’s catalytic heart—was enough to turn the Trojan horse away from the gate. Whether such target-site mutations remain rare curiosities or become the next chapter in the Klebsiella resistance story will depend on how quickly surveillance science adapts to watch for them, and how judiciously the world’s remaining last-resort antibiotics are deployed in the years ahead.

Long non-coding RNAs are RNA transcripts longer than about 200 nucleotides that do not encode proteins. Long dismissed as transcriptional noise, they are now recognized as versatile regulators that can modulate chromatin, stabilize or destabilize messenger RNAs, and—critically—serve as competing endogenous RNAs, or ceRNAs, that sponge up microRNAs and thereby protect the genes those microRNAs would otherwise silence. In plants, individual lncRNAs have been linked to drought tolerance, cold acclimation, and pathogen defense, but the field has lacked a systematic answer to a fundamental question: which lncRNAs integrate several stress signals at once, and do they actually do anything? The new study set out to answer both parts.

The computational core of the work is ambitious in scale. Rather than generating new sequencing data, the team mined 447 publicly available RNA-seq datasets from Arabidopsis samples treated with abscisic acid, subjected to drought, or exposed to methyl jasmonate, a volatile derivative of jasmonic acid that the plant deploys when attacked by herbivores and necrotrophic pathogens. Because these datasets came from different laboratories and experimental designs, the researchers applied batch-effect correction using ComBat-seq before reconstructing transcriptomes with StringTie, aligning reads with HISAT2, and systematically filtering candidate transcripts to remove anything with protein-coding potential, as assessed by tools including PLEK, CPAT, and the machine-learning classifier LncDC. The result was a catalogue of 4,176 lncRNAs responsive to abscisic acid, 4,890 to methyl jasmonate, and 4,190 to drought. Strikingly, 54.33 percent of these transcripts had never been annotated before, underscoring how much of the plant transcriptome remains uncharted.

From this raw catalogue, differential expression analysis identified 2,318 abscisic acid-responsive, 2,603 jasmonate-responsive, and 1,788 drought-responsive lncRNAs. The team then intersected the lncRNA loci across all three conditions, a deliberately stringent procedure designed to isolate transcripts whose genomic positions were recovered under every treatment. After filtering, 287 high-confidence multi-stress-responsive lncRNAs emerged—the study’s headline number. Functional enrichment analysis of the protein-coding genes located near these transcripts in the genome, so-called cis-neighboring genes, revealed that the lncRNAs cluster around genes involved in pathogen defense, phytohormone signaling, and abiotic stress responses. In other words, the lncRNAs appear to be embedded in precisely the genomic neighborhoods where a plant would need rapid regulatory control when multiple threats coincide.

To understand how these transcripts might exert their influence, the researchers constructed competing endogenous RNA networks. Using miRBase and plant microRNA databases alongside the PsRobot prediction tool, they identified 232 endogenous target mimics—lncRNAs capable of binding and sequestering specific microRNAs—interacting with 118 distinct microRNAs. The messenger RNA targets of those microRNAs were themselves enriched in hormone signaling, stress response, and core metabolic pathways. This architecture is the classic signature of ceRNA regulation: an lncRNA rises in response to stress, absorbs the microRNA that normally restrains a defensive gene, and the defensive gene’s expression consequently climbs. Under this model, mslncRNAs function not as passive byproducts of stress but as molecular nodes—relay points through which the abscisic acid, drought, and jasmonate pathways can communicate with one another.

Computational predictions, however, are only hypotheses until they survive contact with living plants. The team selected two candidates, mslncRNA-84 and mslncRNA-189, for experimental validation. Quantitative reverse-transcription PCR confirmed that both transcripts were induced by abscisic acid, drought, and methyl jasmonate, matching the in silico expression predictions with gratifying fidelity. The researchers then took a decisive step that many lncRNA studies omit: they obtained T-DNA insertion lines in which the genes encoding these transcripts are disrupted, allowing direct functional tests rather than correlation-based inference.

The mutant assays spanned the full breadth of the three stress pathways. In germination assays, seeds carrying disruptions in the candidate lncRNAs displayed altered sensitivity to abscisic acid, a hormone that normally arrests germination to prevent seedlings from emerging into dry soil. In jasmonate-dependent growth inhibition assays, which measure the root-growth restraint characteristic of jasmonate signaling, the mutants again behaved differently from wild type, implicating the lncRNAs in jasmonate responsiveness. Biotic stress experiments using the bacterial pathogen Pseudomonas syringae pv. tomato DC3000—a workhorse of plant immunity research—included diaminobenzidine staining to visualize hydrogen peroxide accumulation, trypan blue staining to detect cell death, and colony-forming unit counts to quantify bacterial growth. Drought survival assays completed the picture, testing whether the lncRNAs contribute to the plant’s capacity to withstand water deprivation. Collectively, these results support the conclusion that mslncRNA-84 and mslncRNA-189 are genuine candidate regulators associated with phytohormone signaling, defense responses, and drought adaptation.

The significance of the work extends well beyond Arabidopsis. As climate change intensifies, crops increasingly face combinations of stresses—heat plus drought, drought plus pathogen pressure—rather than single insults, and research has shown that plant responses to combined stresses are not simple sums of the individual responses. Hormone crosstalk lies at the heart of this complexity: abscisic acid governs stomatal closure and dehydration tolerance, while jasmonates orchestrate wound and pathogen defense, and the two pathways engage in reciprocal regulation that determines whether a plant prioritizes growth, defense, or survival. If lncRNAs such as mslncRNA-84 and mslncRNA-189 help arbitrate that arbitration itself, they represent attractive targets for engineering crops that maintain resilience without sacrificing yield. Previous work on individual lncRNAs—for example, DANA1, which promotes drought tolerance in Arabidopsis through histone deacetylation, or ARTA, which controls abscisic acid responses via nuclear trafficking of the transcription factor MYB7—demonstrated that manipulating single lncRNAs can have meaningful physiological consequences. The new study supplies a shortlist of 287 additional candidates, many of them entirely novel, for that kind of mechanistic dissection.

The methodological approach also offers a template for other systems. By leveraging hundreds of existing public datasets rather than generating new ones, the study shows how the ever-growing repositories of plant RNA-seq data can be repurposed for discovery, provided researchers carefully control for batch effects and apply rigorous coding-potential filtering. The strategy of intersecting genomic loci across treatments to define a high-confidence core set is conservative, which means the 287 mslncRNAs are likely the tip of the iceberg; transcripts responsive to only two of the three stresses, or those detected at lower abundance, were excluded. The authors’ ceRNA network analysis likewise provides a mechanistic framework that can be tested in other species where drought and jasmonate responses intersect, from staple cereals to horticultural crops.

Important questions remain. T-DNA insertion lines can have background mutations, and the precise molecular mechanisms by which mslncRNA-84 and mslncRNA-189 act—whether through microRNA sponging, chromatin modification, or direct interaction with other RNAs—will require targeted experiments such as microRNA co-immunoprecipitation, transcript localization studies, and rescue assays. The generalizability of the ceRNA model in plants, where small RNA targeting tends to be more direct than in animals, is still debated. Nevertheless, by combining genome-wide prediction, network modeling, and bona fide genetic validation in a single study, the Xi’an team has moved the field a substantial step closer to understanding how plants compute decisions at the intersection of drought and defense. For a world confronting increasingly unpredictable growing conditions, that computational and molecular map of 287 regulatory RNAs may prove to be one of the more consequential datasets in plant stress biology.

Ataxia with vitamin E deficiency, or AVED, is an autosomal recessive disorder caused by pathogenic variants in both copies of the TTPA gene, which encodes the alpha-tocopherol transfer protein. This protein, located primarily in the liver, is responsible for selectively packaging alpha-tocopherol—the biologically most active form of vitamin E—into very-low-density lipoproteins for distribution to tissues. When the protein fails, vitamin E is not retained in the body, and the resulting deficiency progressively damages the nervous system, particularly the cerebellum and the long tracts of the spinal cord. Patients typically present in childhood or early adulthood with progressive gait instability, poor coordination, slurred speech, and loss of reflexes, a clinical picture that closely mimics Friedreich’s ataxia.

The reason AVED attracts such attention in the neurology and genetics communities is that it is, in principle, treatable. High-dose oral vitamin E supplementation can raise serum levels of the vitamin and, if started early enough, may prevent or even partially reverse neurological damage. The tragedy of the disease lies in delayed diagnosis: because the symptoms overlap with genetically distinct and untreatable ataxias, many patients go years without the correct answer, during which irreversible neuronal loss accumulates.

The patient in the new report is a 34-year-old woman with childhood-onset progressive ataxia. The investigative team combined clinical examination, biochemical measurements, neuroimaging, and electrophysiological testing with whole-exome sequencing, a technology that reads the protein-coding regions of the genome. Her baseline serum vitamin E level was profoundly low at 0.8 micrograms per milliliter, a value consistent with the severe loss of alpha-tocopherol transfer function that defines AVED.

Sequencing revealed something unusual. Within the TTPA gene, two substitutions were found at positions 296 and 299 of the coding sequence—sites separated by only three nucleotides. Individually, the variants read as c.296G>A and c.299A>C, but because they are adjacent within the same codon neighborhood, the combined effect is best described as a complex allele: at the protein level, the two neighboring amino acids glycine 99 and tyrosine 100 are deleted and replaced by aspartic acid and serine, an event annotated as p.Gly99_Tyr100delinsAspSer. Both altered residues are evolutionarily conserved and lie within the CRAL-TRIO domain, the structural pocket of the alpha-tocopherol transfer protein that grips and shuttles vitamin E. Given that domain’s central role in ligand binding, disrupting two consecutive residues within it is highly suggestive of functional impairment.

Determining that both substitutions sit on the same chromosome copy, rather than one on each, was not a formality—it was the crux of the diagnosis. For an autosomal recessive disease, the patient needed both defective copies of TTPA. If the two variants were on opposite chromosomes, each copy would carry only a single change, and the picture would be more ambiguous. The researchers addressed this through read-level inspection of the sequencing data: when individual sequencing reads spanning both positions are examined, reads carrying both substitutions simultaneously reveal that the mutations are physically linked in cis. Sanger sequencing, the classical gold-standard confirmation method, then showed that the woman was homozygous for the complex allele while both of her parents were heterozygous carriers—the precise segregation pattern expected for a recessive disease.

This case underscores a growing problem in clinical genomics: multi-nucleotide variants, or MNVs, are systematically under-recognized. Most standard variant-calling pipelines call each nucleotide change independently, and databases frequently annotate adjacent substitutions as separate entries. When the two changes affect the same codon, their combined protein-level consequence—a deletion-insertion event in this case—is fundamentally different from two independent missense changes. Misannotation of MNVs can therefore lead to incorrect predictions of pathogenicity, incorrect protein models, and potentially misdiagnosis. Earlier surveys of large exome and genome datasets have shown that MNVs occur at appreciable frequency across the human genome, and clinical genetics guidelines now urge laboratories to evaluate closely spaced variants jointly rather than in isolation.

To assess the plausibility that the complex allele is pathogenic, the team turned to population databases, computational prediction tools, and exploratory structure-based analysis. The variant is absent or vanishingly rare in general population catalogs, consistent with a rare disease allele. In silico predictors, which score the likelihood that an amino acid substitution damages protein function, flagged the altered residues as deleterious. Computational modeling of the protein structure suggested that the double substitution would alter local interactions of residues within or near the vitamin E binding pocket, plausibly compromising the architecture that allows the transfer protein to recognize alpha-tocopherol selectively among the family of tocopherol and tocotrienol isoforms. The authors are careful, however, to note the limits of this evidence: no laboratory functional assay was performed, so the precise effect of the allele on protein stability, vitamin E binding, or lipid transfer activity could not be directly established. Structure-based prediction points toward damage but does not prove it.

The therapeutic dimension of the case offers a measure of hope. Following diagnosis, the patient began high-dose vitamin E supplementation, and her serum levels were tracked longitudinally. After twelve months of treatment, her vitamin E level had risen from 0.8 to 7.5 micrograms per milliliter—an essentially complete biochemical correction. More strikingly, clinicians qualitatively observed improvements in gait stability, coordination, speech, and fine motor performance over the same period. The temporal association between biochemical normalization and clinical gains suggests that even in adulthood, decades after symptom onset, some neurological function may remain recoverable or at least stabilizable when the underlying deficiency is corrected. The authors appropriately frame these observations cautiously: the clinical improvements were qualitative rather than quantitatively scored, and spontaneous fluctuation cannot be excluded. Still, the report joins a body of literature showing that AVED responds to supplementation and adds weight to the argument that adult diagnosis is not a reason to withhold therapy.

Familial segregation testing also carries practical implications beyond the index patient. Because both parents are carriers, each future pregnancy for them carries a 25 percent recurrence risk, and siblings of the patient have defined probabilities of being carriers or affected. Identification of the familial variant enables targeted carrier testing and, if desired, prenatal or preimplantation genetic diagnosis—options that are only available once the molecular diagnosis is secure. In populations where consanguinity increases the likelihood of homozygosity for rare alleles, this kind of precise characterization has cascading value for extended families.

What elevates this single case into a broader teaching point is the convergence of two messages. The first is clinical: AVED belongs on the differential diagnosis of progressive ataxia, and measuring serum vitamin E is a cheap, widely available test that can unlock a treatable diagnosis. The second is technical: the era of exome and genome sequencing demands MNV-aware interpretation. Adjacent nucleotide changes must be examined jointly, at the read level when necessary, and confirmed by an orthogonal method such as Sanger sequencing before conclusions about protein consequence and carrier status are drawn. As the authors note, functional studies will be required to determine exactly how the Gly99_Tyr100delinsAspSer allele disrupts the alpha-tocopherol transfer protein, but the clinical, biochemical, and genetic evidence assembled here already expands the known molecular spectrum of AVED and offers a corrective to analytical habits that remain common in diagnostic laboratories.

The research team, led by Behire Sançar and colleagues, defines bad news in the clinical context as information about a serious diagnosis, an unfavorable turn in treatment, or any revelation that negatively alters how patients envision their future. Communication of this kind is not merely a courtesy; it is an ethical obligation with measurable consequences for psychological adjustment, trust in care teams, and downstream health outcomes. Nurses occupy a unique position in this process because they have the closest and most sustained contact with patients, meaning they often absorb the first wave of fear, grief, and questioning that follows a diagnosis. Previous studies have repeatedly shown that nurses feel poorly prepared for these encounters, reporting inadequate training, difficulty choosing appropriate communication methods, and difficulty carrying the emotional burden, which in turn contributes to occupational stress and burnout.

To quantify perceived knowledge and skill, the researchers administered the Bad News Delivering Scale for Health Professionals, a validated instrument developed by González-Cabrera and colleagues and adapted into Turkish by Karataş Baran and colleagues. The scale comprises items scored on a three-point Likert range from “never” to “always,” yielding total scores between 21 and 63, with higher values indicating greater perceived ability. The instrument demonstrated excellent internal consistency in this sample, with a Cronbach’s alpha of 0.94, compared with 0.87 in the Turkish adaptation study. Participants also completed a 12-item descriptive form covering demographics, clinical unit, self-assessed ability, and history of negative experiences. Data were collected face-to-face in November and December 2024, each interview lasting roughly 20 minutes, and no missing data were recorded because questionnaires were checked for completeness on the spot.

The sample size was determined a priori using G*Power 3.1.9.2 software, which indicated a minimum of 324 participants at 95 percent power and an effect size of 0.402; the final cohort of 375 nurses comfortably exceeded this threshold. The demographic profile reflected the profession’s composition: 75.2 percent of respondents were female, 66.9 percent married, and 77.3 percent held bachelor’s degrees, with an average age of 34.60 years and an average of 11.43 years of professional experience. Participants were drawn from surgical and internal medicine wards, intensive care units, pediatrics, polyclinics, emergency services, and operating theatres. Because the score distributions deviated from normality, the team applied non-parametric statistics throughout, using the Kolmogorov-Smirnov test to confirm distribution shape, the Mann-Whitney U test for two-group comparisons, the Kruskal-Wallis H test for multiple groups with Bonferroni-corrected post hoc procedures, and Spearman correlation for continuous associations.

The headline result was a mean BNDS score of 54.62 out of a possible 63, a figure the authors characterize as relatively high and consistent with comparable studies using the same scale and with SPIKES-based assessments in other countries. Yet beneath that reassuring average lay striking disparities in preparation and role perception. Only 7.7 percent of nurses had ever received specific training in delivering bad news. Even more revealing, 85.6 percent believed that breaking bad news was not part of a nurse’s professional duty, and only four respondents—about one percent—considered it their responsibility. When asked to evaluate their own ability, 42.7 percent rated themselves as moderate, 20.3 percent as bad, and 14.4 percent as very bad, while fewer than a quarter described themselves as good or very good.

Statistical comparisons uncovered several significant moderators of perceived skill. Female nurses scored higher than male colleagues (mean 55.36 versus 52.37; p = 0.038, r = 0.124), a result consistent with a broader literature linking female healthcare professionals to stronger empathy and communication performance. Postgraduate-educated nurses outperformed both associate- and bachelor’s-degree holders (p = 0.002), echoing prior Turkish findings that advanced academic training confers an edge in therapeutic communication. Clinical setting mattered too: nurses in pediatric wards scored higher than those in internal medicine, and polyclinic nurses scored higher still (p = 0.009), possibly because outpatient staff interact with a larger and more diverse stream of patients and families, honing their empathic and problem-solving repertoire. Interestingly, whether a nurse had received special training made no significant difference to scale scores, a paradox the authors attribute to the fact that so few had such training and to the dominant influence of general vocational education.

Correlation analysis added a developmental dimension. Age showed a weak but significant positive association with BNDS scores (r = 0.178, p < 0.01), as did years of professional experience (r = 0.186, p < 0.01), suggesting that communication finesse in crisis conversations matures over a career, perhaps as nurses learn to manage their own emotions while navigating those of patients and relatives. Notably, the number of bad news deliveries per month—which averaged a mere 0.72—showed no relationship with skill scores, implying that frequency of exposure alone does not build competence in the absence of deliberate training and feedback. The findings align with earlier work reporting that nurses with two decades or more of experience communicate significantly better, though the literature is not unanimous; at least one study found communication skills declining with age, possibly reflecting occupational fatigue.

The discussion grapples with the most puzzling finding: nurses’ widespread denial that bad news delivery falls within their remit, even though the literature consistently frames it as a core nursing care activity. The authors suggest a self-reinforcing loop. Because nurses see the task as physicians’ responsibility, they do not seek specialized training; because they are untrained, they avoid the task and defer it upward, leaving patients’ emotional needs inadequately addressed. They also point to structural barriers nurses themselves cite, including limited time, fear of being unable to respond adequately, communication obstacles, violence from patients and relatives, and unsuitable environments. While established protocols—the SPIKES framework of Baile and Buckman, the ABCDE approach of Rabow and McPhee, and the algorithms of Girgis and Sanson-Fisher—offer guidance, the study notes these protocols are rarely implemented effectively in practice, and their success depends heavily on nurses’ education, experience, and institutional support.

Nurses who rated their own ability as good, moderate, or even bad scored higher on the scale than those who rated themselves very bad, while those reporting no negative experiences outscored those who were undecided—patterns suggesting that extreme self-doubt and ambiguity about one’s role both track with lower perceived competence. The authors interpret these effects cautiously, given the small effect sizes typical of the analysis (η²H values between 0.038 and 0.053, mostly below the conventional medium threshold) and the self-report nature of the data, which carries risks of social desirability bias, particularly with face-to-face interviews conducted by a researcher employed at the same hospital.

The study’s implications reach directly into nursing education and health policy. The authors call for structured communication training to be embedded in undergraduate curricula and in-service programs, for mentoring models that support nurses through emotionally difficult conversations, and for institutional policies that explicitly define nurses’ roles in breaking bad news and foster interdisciplinary collaboration. They further recommend that hospitals monitor bad news delivery as a quality and safety indicator. The limitations are candidly acknowledged: a single-center design that may not generalize, reliance on self-report without objective verification or patient outcome measures, a restricted set of variables, and a cross-sectional architecture that precludes causal inference. Even so, as hospitals worldwide confront workforce strain and rising expectations for patient-centered communication, the message from this Turkish cohort is clear: the professionals closest to the patient’s moment of distress are being asked to carry it largely unprepared, and closing that gap may be one of the most cost-effective investments a health system can make.

Doxorubicin, an anthracycline antibiotic discovered more than half a century ago, remains one of the most effective chemotherapy agents ever developed. It works by inhibiting topoisomerase II, an enzyme essential for DNA replication, thereby blocking the uncontrolled cell division that drives tumor growth. But its success comes with a devastating trade-off. Clinical analyses have reported occurrence rates of roughly 6 percent for clinically overt cardiotoxicity and 18 percent for subclinical cardiotoxicity among patients treated with the drug, and other studies have found cardiac dysfunction ranging from 30 percent in adult survivors to as much as 60 percent in children. Doxorubicin-induced congestive heart failure is unpredictable, carries a poor prognosis independent of cancer outcomes, and currently cannot be predicted with any validated clinical biomarker.

The clinical challenge lies in the drug’s insidious mechanism of harm. Cardiac toxicity typically begins as subclinical myocardial injury, followed by an early and often asymptomatic decline in the left ventricular ejection fraction, or LVEF, a measure of how much blood the heart pumps with each contraction. By the time symptoms of heart failure appear, damage may already be irreversible. Echocardiography and radionuclide angiography can monitor ventricular function, but the former is operator-dependent while the latter exposes patients to radiation. Cardiac troponins, the standard blood markers of heart muscle injury in emergency settings, have not been validated for detecting chemotherapy-related cardiotoxicity in clinical studies.

The UAMS team enrolled 27 patients with early-stage breast cancer who were scheduled to receive a predefined regimen of doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²) for four cycles every two weeks at the Winthrop P. Rockefeller Cancer Institute. Blood was drawn at two points: before chemotherapy began, designated T0, and after the first cycle, designated T1. Cardiac function was assessed with multigated acquisition (MUGA) scans at baseline and after the fourth cycle. Patients whose LVEF declined more than 10 percentage points from baseline or fell below 50 percent were classified as the abnormal cardiotoxicity group, while those with a decline of 10 points or less and a post-treatment LVEF of at least 50 percent formed the normal group. Eight patients ultimately fell into the abnormal group and 19 into the normal group.

Plasma samples were processed under strict protocols and shipped frozen on dry ice to Metabolon, Inc., in Durham, North Carolina, for untargeted metabolomic profiling. The platform used a Waters ACQUITY ultra-performance liquid chromatography system coupled to a Thermo Scientific Q-Exactive high-resolution mass spectrometer with a heated electrospray ionization source and Orbitrap mass analyzer. Metabolites were identified by matching ion features against a library of 3,300 purified standard compounds using three criteria: retention index, accurate mass within 10 parts per million, and MS/MS spectral comparison. The raw assay yielded 1,285 metabolites, which were filtered for missing values and low variability, log-transformed, and quality-controlled to produce a final dataset of 54 samples and 1,124 metabolites, of which 913 were chemically annotated.

Statistical analysis of baseline samples, before any chemotherapy had been administered, revealed a striking separation in plasma metabolomic profiles between the two groups, confirmed by principal component analysis. A univariate screen identified 100 metabolites significantly different between the groups at baseline, of which 78 were chemically annotated. Patients who would go on to develop cardiotoxicity showed elevated levels of dicarboxylic fatty acids such as sebacate (a ten-carbon dicarboxylate, with a log2 fold change of 1.33 and a p-value of 0.005) and suberate (an eight-carbon dicarboxylate), along with taurine, inosine, sphingosine, and oxindolylalanine. At the same time, they showed depressed levels of key antioxidant vitamins, including retinol (vitamin A, log2 fold change of −0.54) and alpha-tocopherol (vitamin E, log2 fold change of −1.90), along with reduced pyruvate, a central metabolite of energy metabolism, and diminished phospholipids involved in membrane structure. The researchers interpreted these patterns as evidence of pre-existing impairment in mitochondrial fatty acid oxidation and compromised antioxidant defenses in patients destined for heart injury.

A second analytical strategy tracked how metabolite levels changed dynamically during treatment. Using linear mixed-effects models adjusted for age, race, and body mass index, the team identified 78 metabolites whose trajectories over the first chemotherapy cycle differed significantly between groups. Ten metabolites overlapped between the baseline and longitudinal analyses, including 3-phosphoglycerate, inosine, taurine, suberate, sebacate, and sphingadienine, forming a focused candidate biomarker panel. Pathway enrichment analysis of these longitudinal changes pointed to significant disruptions in three interconnected metabolic networks: galactose metabolism, involving glycerol and sorbitol; purine metabolism, involving xanthine, adenosine, and inosine; and beta-alanine metabolism, involving spermidine and ureidopionic acid. These findings suggest that chemotherapy shifts carbohydrate, nucleotide, and amino acid metabolism in ways that may amplify cardiac vulnerability.

To translate the statistical findings into predictive power, the researchers turned to machine learning. They first narrowed the metabolite lists using stepwise logistic regression guided by the Akaike Information Criterion, then trained Random Forest classifiers with leave-one-out cross-validation to make maximum use of the small sample. At baseline, two metabolites emerged as the strongest predictors: sebacate (importance score 100) and 2-hydroxyhippurate, a xenobiotic metabolite also known as salicylurate (importance score 62.17). The baseline model achieved an accuracy of 81.5 percent and a receiver operating characteristic area under the curve of 0.855, with high specificity of 89.5 percent but moderate sensitivity of 62.5 percent. A second model built on longitudinal changes from the first chemotherapy cycle identified orotate (importance 100), picolinate (importance 55.48), and suberate (importance 44.12) as key predictors, achieving 80 percent accuracy and an AUC of 0.798, again with high specificity and lower sensitivity. The pattern of high specificity with limited sensitivity suggests these markers are more effective at confirming low risk than at catching every case of developing cardiotoxicity, a limitation the authors attribute to the small cohort and class imbalance.

The biological significance of these candidates is rooted in well-characterized cardiac physiology. Dicarboxylic acids such as sebacate and suberate are products of omega-oxidation, an alternate fatty acid breakdown pathway in the endoplasmic reticulum that activates when mitochondrial beta-oxidation is impaired. Elevated levels suggest fatty acid overflow and insufficient carnitine availability, processes that strain mitochondria, impair contractility, and promote cardiac cell death. Elevated orotate, an intermediate in pyrimidine biosynthesis, has previously been linked to endothelial dysfunction through disruption of insulin- and metformin-induced nitric oxide production in blood vessel cells. Picolinate, a metabolite of the tryptophan-kynurenine pathway, has been associated with coronary heart disease and belongs to a family of metabolites implicated in both neuroprotection and neurotoxicity, hinting at systemic connections between chemotherapy’s cardiac and cognitive side effects.

The authors caution that the study is exploratory and has important limitations. With 27 participants, statistical power is limited and the risk of overfitting is real. Screening thresholds were deliberately lenient, and false discovery rate correction was not applied, making the findings hypothesis-generating rather than definitive. Concomitant medications, including beta-blockers and metformin, may have influenced metabolomic profiles, and plasma metabolomics reflects systemic metabolism rather than direct evidence of cardiomyocyte-specific injury. Nevertheless, the research, funded by the National Institute of General Medical Sciences and published in the journal Metabolomics, demonstrates that the blood of patients at risk of chemotherapy heart damage tells a chemically distinct story before treatment even begins. If validated in larger cohorts, such metabolomic signatures could enable clinicians to personalize doxorubicin dosing, deploy cardioprotective strategies preemptively, and preserve the anticancer power of one of oncology’s most valuable weapons without sacrificing the hearts of the patients it saves.

The research, led by Stivenn Gutiérrez, Vanessa Urrea, Luz H. Patiño and Juan David Ramírez of the Universidad del Rosario in Bogotá, together with collaborators at the Universidad de Nariño, the Universidad Nacional de Colombia and the University of South Florida, focused on a region where parasite transmission is poorly documented. Giardia duodenalis and Cryptosporidium species are single-celled protozoan parasites responsible for some of the most common waterborne diarrheal illnesses worldwide, with substantial public health consequences and zoonotic potential. Both organisms form tough, environmentally resistant cysts and oocysts that persist in water for months, resist routine chlorination, and can trigger outbreaks when sanitation infrastructure fails.

Traditional molecular surveillance of these parasites has relied on Sanger sequencing, a technology that reads the dominant genetic signal in a sample but struggles when multiple parasite strains or species are present simultaneously. Because water is a complex environmental matrix, mixed infections and minority variants are common—but Sanger-based genotyping frequently collapses this diversity into a single consensus sequence, underestimating the true range of genotypes circulating in a watershed. The Colombian team set out to address this blind spot by adopting Oxford Nanopore Technologies (ONT), a long-read sequencing platform that produces high-depth data in real time from a device small enough to fit in a backpack.

Between August 2022 and March 2023, the researchers collected 102 water samples over seven months from four points across the study area: three surface water sites representing the upper, middle and lower reaches of the Río Pasto basin, and one wastewater collection point in the city of Pasto, the capital of Nariño department. This sampling design allowed the team to track how parasite genetic diversity changed along the river’s course, from relatively pristine highland stretches to areas receiving urban discharge.

At the heart of the study was a technical innovation. The team designed and validated a novel set of primers targeting the 18S ribosomal RNA gene of Cryptosporidium, complementing previously published primer sets for three genetic loci in G. duodenalis: the glutamate dehydrogenase gene (gdh), the triose phosphate isomerase gene (tpi), and the beta giardin gene (bg). Using multiple loci rather than a single marker is what defines this as a multilocus approach, giving researchers several independent windows into the parasites’ genetics. PCR-amplified DNA from these targets was then sequenced on a MinION Mk1C nanopore device for 72 hours per run.

The bioinformatic pipeline was equally carefully constructed. Raw nanopore reads were filtered for quality at a Phred score of at least 10, ensuring that low-confidence base calls were removed before analysis. The surviving reads were taxonomically assigned using Centrifuge, a rapid classifier that aligns reads against curated reference databases of known parasite sequences. To guard against spurious assignments, the team imposed a strict threshold: a taxon was only considered genuinely present in a sample if at least 1,000 reads supported it. This conservative criterion reduces the risk that sequencing noise or cross-contamination would be mistaken for real detections.

The results for Giardia duodenalis were striking. Of the 102 water samples, 49—or 48 percent—yielded at least one PCR-positive amplicon for the parasite. Nanopore sequencing and quality filtering then delivered valid taxonomic assignments in 26 of 32 samples (81.3 percent) for the beta giardin locus, 35 of 40 samples (87.5 percent) for glutamate dehydrogenase, and 27 of 33 samples (81.8 percent) for triose phosphate isomerase. These high assignment rates demonstrate the robustness of the multilocus strategy even in environmentally degraded water samples where DNA is often fragmented and present at low concentrations.

Genetic assemblages of G. duodenalis—the parasite’s equivalent of subspecies, some of which differ in host range and zoonotic risk—were distributed in patterns that differed between water types. In surface water, assemblage A predominated across loci, accounting for a mean relative read abundance of 80.7 percent at the beta giardin marker and 53.8 percent at glutamate dehydrogenase. Assemblage A is significant because it is one of the assemblages most commonly associated with human infection. In wastewater, the picture shifted: assemblage B became more prevalent at the gdh locus with a mean abundance of 51.5 percent, while assemblage A remained dominant at beta giardin with 66.7 percent. Lower-level detections of assemblages C through E—typically associated with dogs, cats and livestock—also appeared, mostly through the gdh marker, hinting at animal contributions to water contamination in the basin.

At an even finer resolution, the sub-assemblage level revealed that AII was the most consistently dominant lineage across both surface water and wastewater and across all three loci. Crucially, the researchers documented co-occurrence of multiple sub-assemblages within single samples across all three genetic markers—exactly the kind of mixed signal that Sanger sequencing would have flattened into a single genotype. This confirms that single infections are the exception rather than the rule in environmental samples from this region.

For Cryptosporidium, the numbers were even more remarkable. Sixty-seven of the 102 samples (65.7 percent) tested positive by PCR, and 49 of those (73.1 percent) produced valid species-level assignments after nanopore sequencing. Cryptosporidium parvum—a species of major medical and veterinary importance, capable of infecting humans, cattle and wildlife—was the most abundant organism, with mean relative read abundances of 40.2 percent in surface water and 32.9 percent in wastewater. It was followed by C. andersoni, primarily a bovine parasite, and C. canis, a dog-associated species. The co-presence of human-relevant and animal-associated species in the same waters points toward a complex contamination landscape involving both human sewage and livestock runoff.

The co-detection statistics were particularly noteworthy. In 47 of the 49 assigned Cryptosporidium samples—95.9 percent—two or more species were detected simultaneously, most frequently the combination of C. parvum, C. andersoni and C. canis, which occurred together in 36.7 percent of assigned samples. The authors are appropriately cautious about interpreting this figure, noting that it may partly reflect the limited species-resolving power of single-locus 18S rRNA genotyping combined with the extraordinary sensitivity of high-depth long-read sequencing. In other words, the technology may be revealing true co-infections, but some apparent co-detections could also stem from closely related sequences that single-locus data cannot fully discriminate. Either way, the study shows that environmental Cryptosporidium populations are far more complex than single-marker methods suggest.

Crossing between the two parasites, the team found that in 27 of 69 assigned samples—39.1 percent—both at least one Cryptosporidium species and at least one Giardia assemblage were present concurrently. Nearly four in ten water samples therefore carried a double burden of the two most notorious protozoan diarrheal agents, reinforcing concerns about the cumulative microbial risk faced by communities that rely on the Río Pasto for agriculture, recreation and drinking water upstream of treatment.

The implications extend well beyond Colombia. The study demonstrates that a benchtop-scale nanopore workflow—novel primers, multilocus amplicon sequencing, conservative bioinformatic filtering—can deliver genotype-level environmental surveillance at a fraction of the cost and turnaround time of traditional sequencing pipelines. For low- and middle-income settings where Giardia and Cryptosporidium remain endemic and waterborne outbreaks are underreported, such portable, high-resolution monitoring could be transformative. It allows public health authorities to identify which assemblages and species are actually circulating, distinguish human-linked from animal-linked contamination, and target interventions under a One Health framework that integrates human, animal and environmental health.

The authors emphasize an important caveat: detecting parasite DNA does not by itself quantify infectious risk. Viability of cysts and oocysts, parasite concentrations in the water, and actual exposure pathways all require complementary measurement. Nevertheless, the documented breadth of genetic diversity in the Río Pasto basin provides a critical baseline for future surveillance and a proof of concept that multilocus nanopore sequencing can expose the mixed infections and minority variants that older methods have long overlooked. In a world increasingly focused on pathogen genomics, this study makes a compelling case that the future of waterborne disease monitoring may lie in small sequencers listening to the full chorus of parasites in a single river sample.

The study, published in Virology Journal, examined cerebrospinal fluid samples from 46 pediatric patients who arrived at hospital with clinical suspicions of viral central nervous system infection. Using a highly sensitive molecular technique known as TaqMan probe-based quantitative polymerase chain reaction, the team, led by Negar Hemmati and Bahman Abedi Kiasari of the University of Tehran together with Fatemeh Hoda Fallah of Valiasr and Imam Khomeini Hospitals at Tehran University of Medical Sciences, searched the samples for the genetic fingerprint of Merkel cell polyomavirus, commonly abbreviated MCPyV. The researchers targeted the viral large T-antigen gene, a regulatory region that is a standard bullseye for polyomavirus detection.

The results were unambiguous in one respect: MCPyV DNA turned up in six of the 46 children, a detection rate of 13 percent. What stunned the investigators was the pattern behind that number. All six MCPyV-positive patients were HIV-positive, an association so strong that the statistical probability of it arising by chance was just 0.001. When the team re-ran their analysis excluding children whose HIV status was unknown, the association held firm at a p-value of 0.002. In a cohort of children suspected of having viral brain infections, the presence of this particular virus appeared to travel exclusively with immune suppression.

Merkel cell polyomavirus is a relative newcomer to the catalogue of human viruses, first identified in 2008 in the tumors that give it its name — Merkel cell carcinoma, a rare but lethal neuroendocrine skin cancer. Like other polyomaviruses, it is a small, double-stranded DNA virus that is ubiquitous in the general population, spreading silently and usually causing no symptoms at all. In healthy individuals, the immune system keeps it in a dormant state. But in people whose immune defenses have collapsed, polyomaviruses can reactivate and, in some cases, invade tissues they would normally never touch. The most infamous example is JC virus, a close relative that causes progressive multifocal leukoencephalopathy, a devastating demyelinating brain disease, in AIDS patients and others with profound immunodeficiency.

The Tehran team did not stop at detection. To guard against the possibility of false positives — always a concern when hunting for viral DNA in clinical samples — they re-tested positive specimens by amplifying an entirely independent genetic target, the viral VP1 gene, which encodes the protein forming the virus’s outer shell. They then performed bidirectional Sanger sequencing on the re-amplified products, essentially reading the actual genetic letters of the virus to confirm that what they had detected was genuinely MCPyV and not a laboratory artifact or a closely related polyomavirus. This two-target confirmation strategy, combined with sequencing, puts the findings on solid molecular ground.

Genetic analysis of the recovered viruses revealed that four isolates belonged to genotype I and two to genotype IIc, showing that at least two distinct viral lineages were circulating in these patients rather than a single clone. This diversity hints that the children may have acquired or harbored separate viral strains, a pattern consistent with independent reactivation events in a suppressed immune environment.

Beyond the mere presence of viral DNA, the study uncovered a telling clinical picture. Compared with children in whom MCPyV was not detected, the six virus-positive patients showed measurable signs of inflammation and biochemical disturbance in their cerebrospinal fluid. Their CSF contained a higher percentage of lymphocytes — 89 percent versus 84 percent in the negative group, a statistically significant difference — indicating a cell-mediated immune response within the central nervous system. Their CSF protein concentrations were elevated, averaging 79 milligrams per deciliter compared with 68 in the negative group, reflecting leakage of proteins across an inflamed blood-brain barrier. At the same time, their glucose concentrations were lower, at 51 versus 55 milligrams per deciliter, a classic sign of metabolically active infectious or inflammatory processes within the fluid bathing the brain and spinal cord.

The clinical differences were just as striking. More than eight in ten MCPyV-positive children — 83.3 percent — presented with altered consciousness, compared with only 37.5 percent of those without detectable virus. Altered consciousness, ranging from confusion to unresponsiveness, is one of the most worrying signs in suspected encephalitis, suggesting that the infection or the immune reaction against it is affecting brain function directly. The association reached statistical significance at a p-value of 0.039. In one of the six positive patients, the researchers also co-detected Epstein-Barr virus DNA, another herpesvirus known to flourish under conditions of immune impairment, adding a further layer of complexity to the viral landscape in these young patients.

The authors are careful to frame their conclusions with appropriate scientific caution. Detecting viral DNA in cerebrospinal fluid does not, by itself, prove that the virus is causing the disease. Viral DNA fragments can persist after infection, low-level latent infection of immune cells trafficking through the central nervous system cannot be excluded, and contamination, however carefully controlled, can never be ruled out entirely in molecular work. What the study establishes is a possible association — MCPyV detection in children with suspected viral CNS infection occurred exclusively in those with HIV and was accompanied by inflammatory CSF abnormalities and more severe neurological presentations. The team explicitly states that these findings suggest a link between MCPyV detection, immunosuppression, and CNS inflammation, but do not establish causality.

Nevertheless, the implications are significant. If MCPyV is confirmed as a genuine neuropathogen, pediatric diagnostic protocols for suspected meningitis and encephalitis — which already routinely screen for herpesviruses, enteroviruses, and in some settings JC virus — may eventually need to add MCPyV to the panel, particularly for children with known or suspected immune compromise. Missed diagnoses of viral CNS infection carry heavy costs: untreated encephalitis can leave children with lasting seizures, cognitive impairment, and developmental delays. A targeted antiviral approach, should one prove effective against MCPyV, would depend first on knowing to look for the virus.

The findings also slot into a growing body of evidence connecting polyomaviruses with neurological disease in the immunosuppressed. Related work has detected JC virus DNA in the CSF of pediatric patients with neurological disorders that do not meet the criteria for progressive multifocal leukoencephalopathy, and earlier research has linked elevated antibody levels against MCPyV with progression to AIDS in HIV-infected adults. The Tehran study is among the first to examine MCPyV specifically in the CSF of children, and its exclusive detection in HIV-positive patients fits neatly into the established paradigm of polyomaviruses as opportunistic agents that emerge when immune surveillance fails.

Why the virus would be present in the central nervous system at all remains an open question. MCPyV normally resides on the skin, where it infects Merkel cells and other cutaneous residents. Routes to the CSF could include hematogenous spread of reactivated virus, carriage within infected immune cells crossing the blood-brain barrier, or reactivation from as-yet unidentified reservoirs in deeper tissues. Answering these questions will require larger, multicenter studies with matched control groups, longitudinal sampling, and perhaps tissue-based analyses capable of demonstrating active viral replication in the nervous system rather than mere molecular presence.

The study’s scale is admittedly modest — 46 patients and six positives — and the authors themselves call for larger multicenter investigations to confirm and extend their results. Yet even at this scale, the statistical signals are hard to dismiss. In a field where the causes of a substantial fraction of pediatric encephalitis cases remain unexplained even after exhaustive testing — a phenomenon clinicians call encephalitis of unknown etiology — any new candidate pathogen deserves attention. Viral screenings that come back negative for the usual suspects leave families without answers and physicians without therapeutic direction. If even a small subset of those mystery cases involves reactivated polyomaviruses in immunocompromised hosts, the Tehran findings could eventually change how those children are evaluated and treated.

The research, which received no specific external funding, was approved by the institutional ethics committee, with written informed consent obtained from the parents or legal guardians of all participants. The team has acknowledged the technical staff of the Clinical Virology Laboratory for their support. The article is published open access under a Creative Commons license, allowing clinicians and researchers worldwide to examine the data in full.

For now, the message for the medical community is one of heightened vigilance rather than alarm. Children with HIV who develop signs of meningitis or encephalitis — fever, headache, neck stiffness, seizures, or altered consciousness — represent a population in whom unusual opportunistic infections must be considered. The discovery that Merkel cell polyomavirus, until now a virus of the skin and the cancer ward, can appear in the spinal fluid of such patients adds one more name to the list of pathogens that physicians caring for immunocompromised children cannot afford to ignore. Whether this virus is a true invader of the nervous system or a molecular bystander, the answer will shape the future of pediatric neurovirology — and the six children in this study have already ensured that the question will not be ignored.